Is there any Takeda original drug for Mobocertinib?

Mobocertinib (Mobocertinib) is a drug used to treat non-small cell lung cancer (Non-Small Cell Lung Cancer, NSCLC). It is a targeted drug that is particularly suitable for patients with EGFR (epidermal growth factor receptor) mutations, especially those with the T790M mutation.

Mobotinib is currently on the market in China. It is an imported Japanese Takeda original drug. However, it is not covered by medical insurance. Patients need to pay for it in full, so the price is very high. Please consult the local hospital pharmacy for specific prices. Other versions include the Hong Kong version of the original drug Mobotinib, which costs around 7,000 to 8,000 yuan. The generic drug of Mobotinib is mainly a Laotian generic drug. The price is about three to four thousand yuan, which is nearly half cheaper than the original drug. The ingredients of the original drug and the generic drug are the same.

EGFR is a protein that is abnormal in some lung cancer patients and can promote tumor growth. Certain drugs can treat lung cancer in these patients by inhibiting EGFR, but over time some patients may develop resistance, particularly to the T790M mutation.

Mobosetinib is a third-generation EGFR inhibitor that has a special effect against the T790M mutation and can help overcome drug resistance. It is an oral drug that inhibits tumor growth by interfering with EGFR signaling, thereby improving the patient's condition.

The use of mobosetinib usually requires a doctor's prescription and requires regular medical monitoring to ensure the effectiveness of the treatment and patient safety. This drug represents an evolving innovation in lung cancer treatment and may provide a treatment option to help patients with EGFR-mutant lung cancer, especially those who have developed resistance to other EGFR inhibitors. However, the specific medication regimen and course of treatment will vary based on the patient's condition and doctor's recommendations. Patients should work with their medical professionals to ensure they receive the most appropriate treatment options.